Loading...
NPI 1134757339 · Troy, MI · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Vibra Of Southeastern Michigan, LLC is a clinical medical laboratory provider located in Troy, Michigan. This profile covers 88 Medicare and 161 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Vibra Of Southeastern Michigan, LLC |
| Address | 1307-a Allen Drive |
| City | Troy |
| State | MI |
| ZIP | 48083 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | April 1, 2020 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $25.7M |
| Medicare | $1.4M |
Payer mix is heavily weighted to Medicaid: lifetime Medicaid revenue is $25.7M compared with $1.4M in Medicare, making Medicaid the dominant source of billed revenue for this NPI. This is not a balanced Medicare/Medicaid operation — the provider functions effectively as a Medicaid-focused laboratory by scale.
The provider’s revenue is concentrated in toxicology and infectious-agent testing across both payers. On Medicare the top three codes (G0480, 80307, G0481) account for 77.3% of Medicare revenue, and on Medicaid the top three (G0480, U0003, 80307) account for 57.2% of Medicaid revenue, indicating a business model centered on definitive drug testing plus high-volume molecular infectious testing.
G0480 is a standout line item on both payers and defines much of the business: Medicare G0480 generated $667.3K (48.9% of Medicare revenue) and ranks #21 of 1590 providers nationally (99th percentile; extreme outlier), while Medicaid G0480 produced $6.6M (27.8% of Medicaid revenue) and ranks #1 of 151 in-state (100th percentile; extreme outlier). These rank and revenue figures identify the provider as an unusually large definitive toxicology operator relative to peers.
The provider also shows extremely high in-state throughput for SARS‑CoV‑2 molecular testing: Medicaid U0003 accounted for $4.5M (19.0% of Medicaid revenue) with 76.6K claims and ranks #5 of 157 in-state (97th percentile; extreme outlier), and Medicaid U0005 logged $1.2M (5.0% of Medicaid revenue) with 65.8K claims (rank #3 of 134, 98th percentile; extreme outlier). These volumes imply high-throughput molecular capacity significant to state-level infectious testing supply.
Medicare activity outside G0480 is meaningful but more typical: 80307 on Medicare generated $200.9K (14.7% of Medicare revenue) and ranks #71 of 4760 providers nationally (99th percentile) while being described as a typical, unremarkable volume for the code; G0481 produced $186K (13.6% of Medicare revenue) and ranks #47 of 1766 (97th percentile; typical, unremarkable). This pattern suggests national-scale concentration is specific to definitive drug testing (G0480) rather than across all lab services.
State-level competitive standing is dominant for multiple Medicaid codes: in addition to G0480 at rank #1, Medicaid 80307 is $2.5M (10.4% of Medicaid revenue) and ranks #3 of 235 in-state (99th percentile; extreme outlier), and 87631 is $1.6M (6.6% of Medicaid revenue) and ranks #2 of 77 in-state (99th percentile; extreme outlier). Collectively these ranks indicate the provider is a major in-state supplier for both toxicology and respiratory molecular testing.
Routine clinical chemistry and common lab panels are present but represent a much smaller share of revenue, serving as secondary lines rather than primary drivers. Examples include 84443 TSH ($24.5K Medicare; $269.5K Medicaid), 80061 lipid panel ($23.1K Medicare; $227.8K Medicaid), 80053 CMP ($22.6K Medicare; $223.2K Medicaid), and 82306 vitamin D ($20.7K Medicare; $424.4K Medicaid); these codes appear at relatively high percentiles for volume but do not approach the revenue concentration of the top toxicology and molecular codes.
The NPI was enumerated on 2020-04-01 (~6 years ago); achieving the reported Medicaid scale ($25.7M lifetime) in that timeframe suggests rapid operational growth and capacity build-out since enumeration. For contracting and competitive assessment, this tenure plus the extreme-volume Medicaid and select Medicare positions signal a laboratory that scaled quickly into specialized high-throughput toxicology and molecular testing services.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
88 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5,960 | $110 | $667.3K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 3,290 | $60 | $200.9K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,220 | $150 | $186K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 220 | $140 | $30.2K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 140 | $200 | $27.7K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 800 | $30 | $27.2K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 340 | $70 | $25.2K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 1,530 | $20 | $24.5K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 1,780 | $10 | $23.1K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 2,260 | $10 | $22.6K |
Showing 1–10 of 88
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 88 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
161 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 91,810 | $70 | $6.6M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 76,560 | $60 | $4.5M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 63,020 | $40 | $2.5M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 10,070 | $160 | $1.6M |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 15,160 | $100 | $1.6M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 65,790 | $20 | $1.2M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 6,660 | $130 | $885.6K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5,510 | $110 | $583.8K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 12,400 | $40 | $458.7K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 20,210 | $20 | $424.4K |
Showing 1–10 of 161
How this provider's Medicaid billing volume and revenue compare to other Michigan providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Michigan median
161 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 11 | 60 | 1,310 | $130 | $1.1M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 25 | 70 | 680 | $100 | $604K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 5 | 160 | 2,720 | $60 | $546.6K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 11 | 50 | 650 | $80 | $298.5K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 150 | 2,250 | $30 | $202.4K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 36 | 180 | 2,600 | $20 | $162K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 17 | 140 | 290 | $80 | $161.3K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 36 | 190 | 2,610 | $20 | $160.2K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 3 | 240 | 2,430 | $20 | $152.2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 3 | 130 | 2,270 | $20 | $140.4K |
Showing 1–10 of 161
Other providers in the same ZIP code as Vibra Of Southeastern Michigan, LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Rhb Laboratories Inc | MI | Clinical Medical Laboratory | $2.9M | $25.3M |
| Pcor LLC | MI | Optometrist | $0 | $25.4M |
| Children's Dental Specialists PLLC | MI | Pediatric Dentistry | $0 | $9.8M |
| National Seating & Mobility Inc | MI | Durable Medical Equipment & Medical Supplies | $0 | $8M |
| Laboratory Corporation Of America | MI | Clinical Medical Laboratory | $1.8M | $3M |
| Alliance Mobile Health Inc | MI | Ambulance | $1.1M | $3.6M |
| Eye Surgery Center Of Michigan LLC | MI | Ambulatory Surgical Clinic/Center | $1.7M | $163.2K |
| Total Lab Solutions LLC | MI | Clinical Medical Laboratory | $638.6K | $768.5K |
| Bernardo Rojas | MI | Internal Medicine Physician | $1.2M | $0 |
| Troy Sc Center LLC | MI | Ambulatory Surgical Clinic/Center | $421.1K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.